B2M and cancer: This is consistent with the notion that complete loss or homozygous inactivation of B2M or IFN-γ pathway genes is not common in cancer (14), highlighting the alternative mechanisms that cancer cells adopt to downregulate MHC-I (13, 14, 16, , –19).